Overview: Gemcitabine as single-agent therapy for advanced breast cancer

Clinical Breast Cancer

Volumn 3, Issue SUPPL. 1, 2002, Pages

  Tripathy, Debu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2 2 difluorodeoxycytidine; Antimetabolites; Phase II trials salvage therapy

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYTARABINE; CYTOTOXIC AGENT; GEMCITABINE; NAVELBINE; NUCLEOSIDE DERIVATIVE; TAXANE DERIVATIVE;

ADVANCED CANCER; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG CHOICE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; QUALITY OF LIFE; SOLID TUMOR;

EID: 0036077791     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.s.002     Document Type: Article

References (26)

1. Cancer statistics, 2001
2. Global cancer statistics
3. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
4. Polychemotherapy for early breast cancer: An overview of the randomised trials
5. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group
6. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
7. Management of metastatic breast cancer: Reasons for optimism
8. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis
9. Cellular elimination of 2′,2′-difluorodeoxycytidine 5′-triphosphate (dFdCTP)
10. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine
11. 2′,2′-difluorodeoxycytidine metabolism and mechanism of action in human leukaemia cells
12. Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides
13. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine
14. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
15. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group
16. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients
17. Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel
18. Advanced breast cancer: A phase II trial with gemcitabine
19. Phase II study of gemcitabine in patients with metastatic breast cancer
20. Single agent gemcitabine as second-and third-line treatment in metastatic breast cancer
21. Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors
22. Gemcitabine (G) in pretreated breast cancer (BC)
23. Single-agent gemcitabine is active in previously treated metastatic breast cancer
24. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
25. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer